title: Median nerve conduction velocity and central conduction time measured with somatosensory evoked potentials in thyroxine-treated infants with Down syndrome.
abstract: OBJECTIVE
  The aim of this study was to determine whether thyroxine treatment would improve nerve conduction in infants with Down syndrome.
  
  
  METHODS
  A single-center, nationwide, randomized, double-blind, clinical trial was performed. Neonates with Down syndrome were assigned randomly to thyroxine (N = 99) or placebo (N = 97) treatment for 2 years. Daily thyroxine doses were adjusted regularly to maintain plasma thyrotropin levels in the normal range and free thyroxine concentrations in the high-normal range. The outcome measures were nerve conduction velocity and central conduction time, determined through median nerve somatosensory evoked potential recording, at the age of 24 months.
  
  
  RESULTS
  At the age of 24 months, somatosensory evoked potential recordings for 81 thyroxine-treated and 84 placebo-treated infants were available for analysis. Nerve conduction velocity and central conduction time did not differ significantly between the 2 treatment groups (nerve conduction velocity: thyroxine: 51.0 m/second; placebo: 50.1 m/second; difference: 0.9 m/second; central conduction time: thyroxine: 8.83 milliseconds; placebo: 8.73 milliseconds; difference: 0.1 milliseconds).
  
  
  CONCLUSIONS
  Postnatal thyroxine treatment of infants with Down syndrome did not alter somatosensory evoked potential-measured peripheral or central nerve conduction significantly. The absence of favorable effects suggests that pathologic mechanisms other than mild postnatal hypothyroidism underlie the impaired nerve conduction. The absence of adverse effects suggests that longstanding plasma free thyroxine concentrations in the high-normal range are not harmful to nerve maturation.
authors.affiliation: Department of Pediatric Endocrinology, Emma Children's Hospital Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. a.s.vantrotsenburg@amc.uva.nl
authors.forename: A S Paul
authors.initials: AS
authors.lastname: van Trotsenburg
authors.forename: Bert J
authors.initials: BJ
authors.lastname: Smit
authors.forename: Johannes H T M
authors.initials: JH
authors.lastname: Koelman
authors.forename: Marijke
authors.initials: M
authors.lastname: Dekker-van der Sloot
authors.forename: Jeannette C D
authors.initials: JC
authors.lastname: Ridder
authors.forename: Jan G P
authors.initials: JG
authors.lastname: Tijssen
authors.forename: Jan J M
authors.initials: JJ
authors.lastname: de Vijlder
authors.forename: Thomas
authors.initials: T
authors.lastname: Vulsma
mesh_terms: D004311:Double-Blind Method; D004314:Down Syndrome / Q000150:complications*; D005073:Evoked Potentials, Somatosensory; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000150:complications / Q000188:drug therapy* / Q000209:etiology*; D007231:Infant, Newborn; D008297:Male; D008475:Median Nerve / Q000502:physiology*; D009431:Neural Conduction; D013974:Thyroxine / Q000627:therapeutic use*
chemical_list: D013974:Thyroxine